

Supplemental file 8. Second malignancies in 21 patients with acute promyelocytic leukaemia (APL)

Sex	Acute promyelocytic leukaemia treatment		Second cancer		
	First line	Second line and beyond	Age at onset (years)	Histology	Years after APL
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	52	Endometrial cancer	24
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	Re-induction: ATRA-idarubicin Autologous HSCT	39	Oesophageal carcinoma	16
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	44	Breast cancer	20
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	Re-induction: AAA + idarubicin Consolidation: AAA + idarubicin Maintenance: AAA	37	Thyroid papillary carcinoma	15
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	Re-induction: AAA + idarubicin Consolidation: AAA + idarubicin Maintenance: AAA	45	Endometrial carcinoma	19
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	50	Myelodysplastic syndrome	6
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	Re-induction: AAA + idarubicin Consolidation: AAA + idarubicin Maintenance: AAA	68	Breast cancer	17
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	44	Nasopharyngeal cancer	1
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	Re-induction: AAA + idarubicin Consolidation: AAA + idarubicin Maintenance: AAA	45	Parotid cancer	1
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	67	Transitional cell carcinoma of ureters	12

F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	58	Lung cancer	3
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	54	Breast cancer	13
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	47	Colorectal cancer	1
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	First re-inductio: AAA + idarubicin Second re-induction: AAA + mitoxantrone Autologous HSCT	59	Myelodysplastic syndrome	8
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	57	Breast cancer	9
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	Re-induction: AAA + idarubicin Consolidation: AAA + idarubicin Maintenance: AAA	44	Colorectal cancer	2
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	57	Renal cell carcinoma	5
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	88	Cholangiocarcinoma	20
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: ATRA-6MP-oral MTX	No	70	Carcinoma of tongue	3
M	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	77	Colorectal carcinoma	4
F	Induction: ATRA-daunorubicin Consolidation: daunorubicin+AraC Maintenance: AAA	No	62	Breast cancer	2

M: male; F: female; ATRA: all-trans retinoic acid; Ara-C: cytarabine; 6MP: 6-mercaptopurine; MTX: methotrexate; AAA: oral arsenic trioxide, ATRA, ascorbic acid; HSCT: haematopoietic stem cell transplantation